trovafloxacin has been researched along with Bacterial Disease in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (70.83) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Amirthaganesan, S; Aridoss, G; Jeong, YT | 1 |
| Cui, HR; Hu, YS; Tang, HB; Wang, JG | 1 |
| Arvis, P; Klossek, JM; Leberre, MA; Nikolaidis, P; Siegert, R | 1 |
| Gooding, BB; Jones, RN | 1 |
| Jones, RN | 1 |
| Finegold, SM; Molitoris, D; Molitoris, E; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| den Hollander, JG; Endtz, HP; Mouton, JW; van den Braak, N; Verbrugh, HA | 1 |
| Appleman, MD; Citron, DM | 1 |
| Ernst, EJ; Ernst, ME; Klepser, ME | 1 |
| Citron, DM; Goldstein, EJ; Hudspeth, M; Hunt Gerardo, S; Merriam, CV | 1 |
| McNabb, J; Nicolau, D; Nightingale, C; Quintiliani, R | 1 |
| Moellering, RC | 1 |
| Amsden, GW; Garey, KW | 1 |
| Godwin, D; Gordon, S; Hemsell, D; Luke, D; Pearlman, M; Roy, S | 1 |
| Rotstein, OD | 1 |
| Bur, F; Donahue, PE; Luke, DR; Mintz, SJ; Smith, DL; Yellin, AE | 1 |
| Hopkins, S; Williams, DJ | 1 |
| Seifert, H | 1 |
| Araki, H; Minami, S; Mitsuyama, J; Narita, H; Takahata, M; Todo, Y; Watanabe, Y; Yamashiro, Y; Yonezawa, M | 1 |
| Hooper, DC | 2 |
| Bradley, JS; Capparelli, EV; Kearns, GL; Reed, MD; Vincent, J | 1 |
| Appelbaum, PC; Credito, KL; Ednie, LM; Jacobs, MR; Khantipong, M | 1 |
8 review(s) available for trovafloxacin and Bacterial Disease
| Article | Year |
|---|---|
Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Case-Control Studies; Child; Child, Preschool; Female; Fluoroquinolones; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Musculoskeletal System; Naphthyridines; Retrospective Studies; Sensitivity and Specificity; Topoisomerase II Inhibitors | 2020 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin | 1997 |
Trovafloxacin: fourth generation fluoroquinolone.
Topics: Adult; Anti-Infective Agents; Bacteria; Bacterial Infections; Child; Connecticut; Drug Evaluation; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines | 1998 |
Trovafloxacin: an overview.
Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Fluoroquinolones; Humans; Multicenter Studies as Topic; Naphthyridines | 1999 |
Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Drug Administration Schedule; Drug Interactions; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Naphthyridines; Prodrugs; Surgical Wound Infection | 1998 |
New uses for new and old quinolones and the challenge of resistance.
Topics: Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sensitivity and Specificity; Sexually Transmitted Diseases; Urinary Tract Infections | 2000 |
The fluoroquinolones after ciprofloxacin and ofloxacin.
Topics: Anti-Infective Agents; Bacterial Infections; Fluoroquinolones; Humans; Naphthyridines; Ofloxacin; Piperazines; Respiratory Tract Infections; Sexually Transmitted Diseases, Bacterial; Skin Diseases, Bacterial; Urinary Tract Infections | 2000 |
4 trial(s) available for trovafloxacin and Bacterial Disease
| Article | Year |
|---|---|
Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Prospective Studies; Quinolines; Treatment Outcome | 2003 |
Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease. Trovafloxacin Surgical Group.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Cefoxitin; Cephamycins; Double-Blind Method; Elective Surgical Procedures; Female; Fluoroquinolones; Humans; Hysterectomy; Hysterectomy, Vaginal; Infusions, Intravenous; Middle Aged; Naphthyridines; Surgical Wound Infection | 1998 |
Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group.
Topics: Abdomen; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Cilastatin; Clavulanic Acid; Double-Blind Method; Female; Fluoroquinolones; Humans; Imipenem; Injections, Intravenous; Male; Middle Aged; Naphthyridines; Penicillins; Prospective Studies; Protease Inhibitors; Surgical Wound Infection; Thienamycins; Treatment Outcome | 1998 |
Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Topics: Adolescent; Anti-Infective Agents; Bacterial Infections; Child; Child, Preschool; Drug Interactions; Fluoroquinolones; Humans; Infant; Injections, Intravenous; Metabolic Clearance Rate; Naphthyridines; Prodrugs | 2000 |
12 other study(ies) available for trovafloxacin and Bacterial Disease
| Article | Year |
|---|---|
Synthesis, crystal and antibacterial studies of diversely functionalized tetrahydropyridin-4-ol.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Crystallography, X-Ray; Humans; Microbial Sensitivity Tests; Models, Molecular; Pyridines | 2010 |
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Fluoroquinolones; Humans; Infant; Microbial Sensitivity Tests; Naphthyridines | 1993 |
In vitro antimicrobial activity of CP-99,219, a new 7-azabicyclonaphthyridone.
Topics: Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin | 1995 |
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines | 1996 |
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
Topics: 4-Quinolones; Anti-Infective Agents; Bacterial Infections; Drug Resistance, Microbial; Endocarditis, Bacterial; Fluoroquinolones; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Naphthyridines | 1997 |
Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
Topics: Abdomen; Anti-Infective Agents; Appendix; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Gangrene; Humans; Microbial Sensitivity Tests; Naphthyridines | 1997 |
Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Bites and Stings; Bites, Human; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Species Specificity; Wound Infection | 1998 |
Trovafloxacin: in vitro activity, pharmacokinetics, and clinical experience. Introduction.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Naphthyridines | 1998 |
Antimicrobial agents for the prevention and treatment of abdominal infections: a new generation?
Topics: Abdomen; Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Fluoroquinolones; Forecasting; Humans; Naphthyridines; Practice Guidelines as Topic; Surgical Wound Infection | 1998 |
Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Bacteria, Aerobic; Bacterial Infections; beta-Lactams; Blood; Culture Media; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Naphthyridines | 1998 |
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Indoles; Injections, Subcutaneous; Isoindoles; Male; Mice; Naphthyridines; Ofloxacin; Quinolones | 1999 |
Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Clindamycin; Drug Synergism; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Time Factors | 2000 |